David Sidransky

90.0k total citations · 24 hit papers
576 papers, 66.1k citations indexed

About

David Sidransky is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, David Sidransky has authored 576 papers receiving a total of 66.1k indexed citations (citations by other indexed papers that have themselves been cited), including 392 papers in Molecular Biology, 188 papers in Oncology and 158 papers in Cancer Research. Recurrent topics in David Sidransky's work include Epigenetics and DNA Methylation (159 papers), RNA modifications and cancer (113 papers) and Cancer-related Molecular Pathways (110 papers). David Sidransky is often cited by papers focused on Epigenetics and DNA Methylation (159 papers), RNA modifications and cancer (113 papers) and Cancer-related Molecular Pathways (110 papers). David Sidransky collaborates with scholars based in United States, India and Italy. David Sidransky's co-authors include Bert Vogelstein, Curtis C. Harris, Monica Hollstein, Wayne M. Koch, James G. Herman, Joseph A. Califano, William H. Westra, Stephen B. Baylin, Mohammad Obaidul Hoque and Jin Jen and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

David Sidransky

567 papers receiving 64.7k citations

Hit Papers

p53 Mutations in Human Cancers 1991 2026 2002 2014 1991 1998 1995 1995 1996 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. p53 Mutations in Human Cancers
    1991 6.7k citations David Sidransky et al. profile →
  2. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.
    1998 3.3k citations David Sidransky, James R. Eshleman et al. profile →
  3. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
    1995 1.7k citations James G. Herman, David Sidransky et al. profile →
  4. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.
    1995 1.2k citations James G. Herman, David Sidransky et al. profile →
  5. Genetic progression model for head and neck cancer: implications for field cancerization.
    1996 1.1k citations Joseph A. Califano, William H. Westra et al. profile →
  6. Head and Neck Cancer
    2001 1.0k citations Wayne M. Koch, David Sidransky et al. profile →
  7. Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
    2006 855 citations Mohammad Obaidul Hoque, James G. Herman et al. profile →
  8. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
    1999 770 citations Montse Sánchez‐Céspedes, David Sidransky et al. profile →
  9. Identification of p53 Gene Mutations in Bladder Cancers and Urine Samples
    1991 731 citations David Sidransky et al. profile →
  10. Facile Detection of Mitochondrial DNA Mutations in Tumors and Bodily Fluids
    2000 692 citations David Sidransky et al. profile →
  11. Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
    2003 667 citations David Sidransky et al. profile →
  12. TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck
    2007 591 citations Maria Luana Poeta, Joseph A. Califano et al. profile →
  13. Molecular Assessment of Histopathological Staging in Squamous-Cell Carcinoma of the Head and Neck
    1995 581 citations Wayne M. Koch, David Sidransky et al. profile →
  14. Clonal expansion of p53 mutant cells is associated with brain tumour progression
    1992 578 citations David Sidransky et al. profile →
  15. DPC4 gene in various tumor types.
    1996 570 citations David Sidransky et al. profile →
  16. Role of the p16 tumor suppressor gene in cancer.
    1998 563 citations David Sidransky et al. profile →
  17. Identification of ras Oncogene Mutations in the Stool of Patients with Curable Colorectal Tumors
    1992 555 citations David Sidransky et al. profile →
  18. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
    1997 552 citations James G. Herman, David Sidransky et al. profile →
  19. Microsatellite alterations in serum DNA of head and neck cancer patients
    1996 552 citations Wayne M. Koch, David Sidransky et al. profile →
  20. Emerging molecular markers of cancer
    2002 523 citations David Sidransky profile →
  21. Association between Cigarette Smoking and Mutation of the p53 Gene in Squamous-Cell Carcinoma of the Head and Neck
    1995 506 citations Wayne M. Koch, David Sidransky et al. profile →
  22. The incidence of p53 mutations increases with progression of head and neck cancer.
    1993 502 citations Wayne M. Koch, David Sidransky et al. profile →
  23. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
    1993 465 citations David Sidransky et al. profile →
  24. Clonal Origin of Bladder Cancer
    1992 428 citations David Sidransky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Sidransky United States 121 40.0k 25.6k 17.1k 11.0k 9.6k 576 66.1k
Ralph R. Weichselbaum United States 107 17.9k 0.4× 18.7k 0.7× 7.6k 0.4× 1.8k 0.2× 10.6k 1.1× 707 48.4k
Curtis C. Harris United States 117 41.1k 1.0× 22.2k 0.9× 24.8k 1.5× 4.9k 0.4× 6.9k 0.7× 579 66.9k
Adrian L. Harris United Kingdom 164 64.9k 1.6× 34.9k 1.4× 45.7k 2.7× 4.8k 0.4× 13.0k 1.4× 1.2k 109.9k
José Baselga United States 98 19.7k 0.5× 25.8k 1.0× 9.8k 0.6× 3.3k 0.3× 14.1k 1.5× 484 46.7k
Adel K. El‐Naggar United States 99 12.0k 0.3× 16.8k 0.7× 5.1k 0.3× 4.3k 0.4× 5.7k 0.6× 679 36.4k
James G. Herman United States 119 50.9k 1.3× 15.1k 0.6× 13.6k 0.8× 8.6k 0.8× 7.6k 0.8× 399 65.8k
Ralph H. Hruban United States 154 29.3k 0.7× 62.5k 2.4× 22.6k 1.3× 7.6k 0.7× 14.2k 1.5× 926 93.4k
David P. Lane United Kingdom 124 37.4k 0.9× 32.2k 1.3× 8.7k 0.5× 4.0k 0.4× 4.2k 0.4× 620 57.7k
Carlos Cordon‐Cardo United States 129 41.4k 1.0× 22.8k 0.9× 12.8k 0.8× 4.2k 0.4× 11.0k 1.1× 564 68.1k
Judah Folkman United States 141 62.8k 1.6× 24.5k 1.0× 29.5k 1.7× 4.7k 0.4× 10.9k 1.1× 395 105.2k

Countries citing papers authored by David Sidransky

Since Specialization
Citations

This map shows the geographic impact of David Sidransky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sidransky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sidransky more than expected).

Fields of papers citing papers by David Sidransky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sidransky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sidransky. The network helps show where David Sidransky may publish in the future.

Co-authorship network of co-authors of David Sidransky

This figure shows the co-authorship network connecting the top 25 collaborators of David Sidransky. A scholar is included among the top collaborators of David Sidransky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sidransky. David Sidransky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Valle, Blanca L., Elisabetta Kuhn, Teresa Díaz-Montes, et al.. (2020). HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. Cancer Prevention Research. 13(9). 783–794. 16 indexed citations
2.
Ooki, Akira, Zahra Maleki, Jun-Chieh J. Tsay, et al.. (2017). A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA. Clinical Cancer Research. 23(22). 7141–7152. 126 indexed citations
3.
Ozawa, Hiroyuki, Evgeny Izumchenko, Eugene Makarev, et al.. (2017). SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clinical Cancer Research. 23(17). 5162–5175. 57 indexed citations
4.
Rettig, Eleni M., Christine H. Chung, Justin A. Bishop, et al.. (2015). Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prevention Research. 8(4). 287–295. 43 indexed citations
5.
Verdura, Sara, Ilse Zondervan, Federica Facchinetti, et al.. (2015). PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Research. 75(7). 1287–1297. 38 indexed citations
6.
Izumchenko, Evgeny, Kai Sun, Siân Jones, et al.. (2014). Notch1 Mutations Are Drivers of Oral Tumorigenesis. Cancer Prevention Research. 8(4). 277–286. 72 indexed citations
7.
Izumchenko, Evgeny, Xiaofei Chang, Christina Michailidi, et al.. (2014). The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors. Cancer Research. 74(14). 3995–4005. 104 indexed citations
8.
Garralda, Elena, Keren Paz, Pedro P. López‐Casas, et al.. (2014). Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research. 20(9). 2476–2484. 107 indexed citations
9.
Park, Il‐Seok, Xiaofei Chang, Myriam Loyo, et al.. (2011). Characterization of the Methylation Patterns in Human Papillomavirus Type 16 Viral DNA in Head and Neck Cancers. Cancer Prevention Research. 4(2). 207–217. 36 indexed citations
10.
Hidalgo, Manuel, Elizabeth Bruckheimer, N.V. Rajeshkumar, et al.. (2011). A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Molecular Cancer Therapeutics. 10(8). 1311–1316. 303 indexed citations
11.
Chang, Xiaofei, Constance L. Monitto, Semra Demokan, et al.. (2010). Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers. Cancer Research. 70(7). 2870–2879. 108 indexed citations
12.
Ostrow, Kimberly Laskie, Mohammad Obaidul Hoque, Myriam Loyo, et al.. (2010). Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR. Clinical Cancer Research. 16(13). 3463–3472. 92 indexed citations
13.
Brait, Mariana, Jean G. Ford, Srinivas Papaiahgari, et al.. (2009). Association between Lifestyle Factors and CpG Island Methylation in a Cancer-Free Population. Cancer Epidemiology Biomarkers & Prevention. 18(11). 2984–2991. 57 indexed citations
14.
Hoque, Mohammad Obaidul, Myoung Sook Kim, Kimberly Laskie Ostrow, et al.. (2008). Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. Cancer Research. 68(8). 2661–2670. 115 indexed citations
15.
Yamashita, Keishi, Myoung Sook Kim, Hannah Lui Park, et al.. (2008). HOP/OB1/NECC1 Promoter DNA Is Frequently Hypermethylated and Involved in Tumorigenic Ability in Esophageal Squamous Cell Carcinoma. Molecular Cancer Research. 6(1). 31–41. 47 indexed citations
16.
Kim, Myoung Sook, Keishi Yamashita, Young Kwang Chae, et al.. (2007). A Promoter Methylation Pattern in the N -Methyl- d -Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma. Clinical Cancer Research. 13(22). 6658–6665. 20 indexed citations
17.
Upadhyay, Sunil, Chunyan Liu, Mohammad Obaidul Hoque, et al.. (2006). LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer. Cancer Research. 66(16). 7870–7879. 37 indexed citations
18.
Kim, Myoung Sook, Keishi Yamashita, Jin Hyen Baek, et al.. (2006). N- Methyl- d -Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer. Cancer Research. 66(7). 3409–3418. 93 indexed citations
19.
20.
Sidransky, David. (1996). Is human patched the gatekeeper of common skin cancers?. Nature Genetics. 14(1). 7–8. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ralph R. Weichselbaum Breakdown of academic impact, for papers by Curtis C. Harris Breakdown of academic impact, for papers by Adrian L. Harris Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by Adel K. El‐Naggar Breakdown of academic impact, for papers by James G. Herman Breakdown of academic impact, for papers by Ralph H. Hruban Breakdown of academic impact, for papers by David P. Lane Breakdown of academic impact, for papers by Carlos Cordon‐Cardo Breakdown of academic impact, for papers by Judah Folkman
Rankless by CCL
2026